M. V. D. Van Der Burg

发表

The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer.

J. Verweij, F. Lammes, M. V. D. Van Der Burg, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

CA 125 in ovarian cancer.

J. Verweij, F. Lammes, M. V. D. Van Der Burg, 1992, The Netherlands journal of medicine.

The role of CA 125 and conventional examinations in diagnosing progressive carcinoma of the ovary.

J. Verweij, F. Lammes, M. V. D. Van Der Burg, 1993, Surgery, gynecology & obstetrics.

Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.

M. J. van den Bent, J. Verweij, J. Schellens, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy.

W. van Putten, G. Stoter, F. Lammes, 1988, Gynecologic oncology.

Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.

J. Verweij, A. Sparreboom, W. Loos, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay.

J. Verweij, A. Sparreboom, W. Loos, 1998, Analytical biochemistry.

Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin.

J. Verweij, A. Sparreboom, P. de Bruijn, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

J. Verweij, W. van Putten, R. de Wit, 2002, British Journal of Cancer.

Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.

J. Verweij, J. Schellens, D. V. Von Hoff, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II study of high-dose megestrol acetate in patients with advanced ovarian carcinoma.

J. Vermorken, S. Pecorelli, N. Rotmensz, 1994, European journal of cancer.

Phase II study of weekly 4'-epidoxorubicin in patients with metastatic squamous cell cancer of the cervix: an EORTC Gynaecological Cancer Cooperative Group Study.

S. Monfardini, J. Vermorken, M. V. D. Van Der Burg, 1992, European journal of cancer.

Phase I study of intravenous fosquidone (GR63178A-NSC D611615) using a three times a week schedule.

J. Verweij, G. Stoter, M. V. D. Van Der Burg, 1992, Clinics in oncology.

Differential modulation of cisplatin accumulation in leukocytes and tumor cell lines by the paclitaxel vehicle Cremophor EL.

J. Verweij, A. Sparreboom, P. de Bruijn, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer.

J. Neijt, P. Willemse, W. W. ten Bokkel Huinink, 1991, European journal of cancer.

Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug.

J. Verweij, H. Pinedo, M. V. D. Van Der Burg, 1987, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects.

J. Verweij, H. Gelderblom, A. Sparreboom, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.

M. J. van den Bent, J. Verweij, J. Schellens, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Carboplatin and cyclophosphamide salvage therapy for ovarian cancer patients relapsing after cisplatin combination chemotherapy.

W. van Putten, G. Stoter, A. Hoff, 1991, European journal of cancer.

Surgical treatment or gastric drainage only for intestinal obstruction in patients with carcinoma of the ovary or peritoneal carcinomatosis of other origin.

P. Siersema, T. Wiggers, B. van Ooijen, 1993, Surgery, gynecology & obstetrics.

Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.

J. Verweij, J. Schellens, G. Stoter, 1995, British Journal of Cancer.

Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute.

S. Rodenhuis, O. Dalesio, A. V. van Oosterom, 1992, Seminars in oncology.

Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer

J. van Houwelingen, W. Boogerd, A. Elderson, 1990, The New England journal of medicine.

The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.

J. Verweij, L. van Zuylen, A. Sparreboom, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer.

J. Verweij, J. Schellens, W. Loos, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bleomycin, methotrexate, and CCNU in advanced inoperable squamous cell carcinoma of the vulva: a phase II study of the EORTC Gynaecological Cancer Cooperative Group (GCCG).

O. Dalesio, C. Mangioni, J. Vermorken, 1990, Gynecologic oncology.

Cyclophosphamide, hexamethylmelamine, adriamycin and cisplatin combination chemotherapy in mixed mesodermal sarcoma of the female genital tract.

J. Verweij, G. Stoter, R. Jansen, 1987, European Journal of Cancer and Clinical Oncology.

Carboplatin in combination therapy for ovarian cancer.

O. Dalesio, J. Vermorken, N. Rotmensz, 1988, Cancer treatment reviews.

Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma.

J. Verweij, R. de Wit, G. Stoter, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of weekly high-dose cisplatin combined with long-term oral etoposide in advanced solid tumors.

J. Verweij, G. Stoter, M. V. D. Van Der Burg, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration.

M. J. van den Bent, W. van Putten, C. Vecht, 1995, European journal of cancer.

Weekly high-dose cisplatin in malignant pleural mesothelioma.

J. Verweij, J. Schellens, G. Stoter, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Asbestos bodies and fibers in lung tissue

J. Verweij, G. Stoter, M. V. D. Van Der Burg, 1974, Environmental Health Perspectives.

Paclitaxel (Taxol) induces cumulative mild neurotoxicity.

M. J. van den Bent, J. V. van Gerven, J. Verweij, 1994, European journal of cancer.

Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies.

J. Verweij, H. Gelderblom, A. Sparreboom, 2002, European Journal of Cancer.

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer.

M. J. van den Bent, J. Verweij, G. Stoter, 1996, British Journal of Cancer.

Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.

J. Verweij, C. Punt, A. Sparreboom, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of flutamide in advanced ovarian cancer: an EORTC Gynaecological Cancer Cooperative Group study.

J. Vermorken, S. Tumolo, M. V. D. Van Der Burg, 1994, European journal of cancer.

Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.

J. Verweij, J. Schellens, W. Loos, 1994, Journal of the National Cancer Institute.

Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer

J. C. Houwelingen, J. Heimans, R. G. van der Hoop, 1990 .

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic malignant melanoma.

J. Verweij, J. Schellens, C. Vecht, 1996, European journal of cancer.

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

J B Vermorken, K. Swenerton, E. Eisenhauer, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The prediction of progression‐free and overall survival in women with an advanced stage of epithelial ovarian carcinoma

D. de Jong, M J C Eijkemans, A C Ansink, 2009, BJOG : an international journal of obstetrics and gynaecology.

Phase II trial of mitozolomide in patients with advanced ovarian cancer. A study of the EORTC Gynecological Cancer Cooperative Group.

M. Piccart, J. Neijt, J. Vermorken, 1989, Acta oncologica.

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.

J. Verweij, J. Schellens, P. Schmitz, 1996, British Journal of Cancer.

Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5.

W. W. ten Bokkel Huinink, H. Pinedo, A. van Oosterom, 1984, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients

M. J. van den Bent, J. Verweij, W. Graveland, 2003, British Journal of Cancer.

Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.

J Verweij, J. Verweij, A. Sparreboom, 1999, Anti-cancer drugs.

A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance.

C. Seynaeve, J. Verweij, H. Herweijer, 1991, British Journal of Cancer.

Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained.

J. Verweij, P. D. De Mulder, P. Schmitz, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study.

C. Mangioni, J. Vermorken, N. Rotmensz, 1985, Gynecologic oncology.

Diagnostic value of anti-neuronal antibodies for paraneoplastic disorders of the nervous system.

S. Henzen‐Logmans, J. Moll, C. Vecht, 1990, Journal of neurology, neurosurgery, and psychiatry.

High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience.

M. Forni, J. Vermorken, G. Bolis, 1995, European journal of gynaecological oncology.

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.

J. Neijt, J. Bouma, W. W. ten Bokkel Huinink, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictability of the survival of patients with advanced ovarian cancer.

J. Neijt, W. W. ten Bokkel Huinink, J. van Houwelingen, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study

M. Piccart, M. Nooij, M. Namer, 2001, Anti-cancer drugs.

A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)

J. Verweij, J. Schellens, D. V. Von Hoff, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin

R. G. van der Hoop, J. van Houwelingen, J. Neijt, 1990, Cancer.

Phase II study of vindesine in disseminated squamous cell carcinoma of the uterine cervix: an EORTC Gynecological cancer Cooperative Group study

M. Piccart, F. Landoni, J. Vermorken, 1991, International Journal of Gynecologic Cancer.

Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin.

J. Verweij, A. Sparreboom, M. D. de Jonge, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors.

J. Verweij, J. Schellens, G. Stoter, 1999, Anti-cancer drugs.

Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix.

O. Dalesio, C. Mangioni, J. Vermorken, 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Phase II study of weekly 4'-epidoxorubicin in patients with metastatic adenocarcinoma of the cervix: an EORTC Gynaecological Cancer Cooperative Group study.

J. Vermorken, D. Curran, G. Bolis, 1997, European Journal of Cancer.

Phase II study of mitomycin-C and cisplatin in disseminated, squamous cell carcinoma of the uterine cervix. A European Organization for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group study.

P. Zola, C. Mangioni, J. Vermorken, 2001, European journal of cancer.

Phase I Study of High-Dose Epirubicin in Platinum-Pretreated Patients with Ovarian Carcinoma

M. Piccart, M. Forni, J. Vermorken, 1999, Oncology.

Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.

J. Verweij, H. V. van Doorn, D. ten Bokkel Huinink, 2014, European journal of cancer.

Multicenter phase II study of spiroplatin.

H. Pinedo, D. Sleijfer, J. Vermorken, 1992, Oncology.

Esorubicin in advanced ovarian epithelial cancer. A phase II study of the EORTC Gynecological Cancer Cooperative Group.

O. Dalesio, M. Aapro, J. Vermorken, 1988, European journal of cancer & clinical oncology.

A phase II study of high dose ifosfamide in metastatic colorectal cancer.

J. Verweij, G. Stoter, A. Hoff, 1989, European journal of cancer & clinical oncology.

Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group.

M. Aapro, M. Namer, I. Vergote, 2003, European journal of cancer.